Thomas J Hwang

List of Publications by Year
in descending order

80	1,921	331670 21	289244 40
papers	citations	h-index	g-index

80	80	80	2863
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Internal Medicine, 2016, 176, 1826.	5.1	279
2	Prices and clinical benefit of cancer drugs in the USA and Europe: a costâ€“benefit analysis. Lancet Oncology, The, 2020, 21, 664-670.	10.7	126
3	Two decades of new drug development for central nervous system disorders. Nature Reviews Drug Discovery, 2015, 14, 815-816.	46.4	111
4	Lifecycle Regulation of Artificial Intelligenceâ€“ and Machine Learningâ€“Based Software Devices in Medicine. JAMA - Journal of the American Medical Association, 2019, 322, 2285.	7.4	86
5	Efficacy, Safety, and Regulatory Approval of Food and Drug Administrationâ€“Designated Breakthrough and Nonbreakthrough Cancer Medicines. Journal of Clinical Oncology, 2018, 36, 1805-1812.	1.6	72
6	Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open, 2014, 4, e004143.	1.9	67
7	Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study. BMJ, The, 2016, 353, i3323.	6.0	66
8	The FDAâ€™s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016. JAMA - Journal of the American Medical Association, 2017, 318, 2137.	7.4	62
9	Association between progressionâ€free survival and patientsâ€™ quality of life in cancer clinical trials. International Journal of Cancer, 2019, 144, 1746-1751.	5.1	62
10	Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ, The, 2020, 371, m3434.	6.0	56
11	Ensuring Access to Injectable Generic Drugs â€” The Case of Intravesical BCG for Bladder Cancer. New England Journal of Medicine, 2017, 376, 1401-1403.	27.0	49
12	Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncology, 2021, 7, e212026.	7.1	46
13	Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study. PLoS Medicine, 2018, 15, e1002520.	8.4	46
14	Postmarketing Trials and Pediatric Device Approvals. Pediatrics, 2014, 133, e1197-e1202.	2.1	39
15	The Pediatric Research Equity Act Moves Into Adolescence. JAMA - Journal of the American Medical Association, 2017, 317, 259.	7.4	38
16	Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act. JAMA Pediatrics, 2019, 173, 68.	6.2	36
17	Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA - Journal of the American Medical Association, 2017, 318, 609.	7.4	28
18	Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19). JAMA Pediatrics, 2020, 174, 825.	6.2	28

#	ARTICLE	IF	CITATIONS
19	Antimicrobial stewardship and public knowledge of antibiotics. Lancet Infectious Diseases, The, 2015, 15, 1000-1001.	9.1	27
20	Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines. Health Affairs, 2018, 37, 724-731.	5.2	27
21	Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic To Translational Science, 2016, 1, 301-308.	4.1	24
22	Pre-market development times for biologic versus small-molecule drugs. Nature Biotechnology, 2019, 37, 708-711.	17.5	24
23	Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies. PLoS ONE, 2013, 8, e71966.	2.5	23
24	Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. Lancet Oncology, The, 2022, 23, 514-520.	10.7	22
25	Drug Safety in the Digital Age. New England Journal of Medicine, 2014, 370, 2460-2462.	27.0	21
26	Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017. JAMA - Journal of the American Medical Association, 2019, 322, 267.	7.4	21
27	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR Public Health and Surveillance, 2018, 4, e1.	2.6	21
28	Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Affairs, 2019, 38, 313-319.	5.2	19
29	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 374-387.	3.8	19
30	Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. Cancer, 2020, 126, 4390-4399.	4.1	19
31	Survey of MD/MBA Programs. Academic Medicine, 2015, 90, 121.	1.6	18
32	Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs. JAMA Internal Medicine, 2019, 179, 374.	5.1	18
33	Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis. Health Affairs, 2020, 39, 1799-1805.	5.2	17
34	Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. Journal of the National Cancer Institute, 2020, 112, 224-228.	6.3	16
35	Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice, 2022, 18, e1522-e1532.	2.9	16
36	Target small firms for antibiotic innovation. Science, 2014, 344, 967-969.	12.6	15

#	Article	IF	Citations
37	Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development. JAMA - Journal of the American Medical Association, 2017, 318, 388.	7.4	15
38	Assessment of US pathway for approving medical devices for rare conditions. BMJ, The, 2014, 348, g217-g217.	6.0	13
39	Quantifying The Food And Drug Administrationâ€™s Rulemaking Delays Highlights The Need For Transparency. Health Affairs, 2014, 33, 309-315.	5.2	12
40	Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007â€“2016. JNCI Cancer Spectrum, 2018, 2, pky016.	2.9	12
41	Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: a national cross-sectional study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1720-1722.	3.0	11
42	Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002-2012. BMJ Open, 2015, 5, e007987-e007987.	1.9	11
43	Paying for innovation: Reimbursement incentives for antibiotics. Science Translational Medicine, 2015, 7, 276fs9.	12.4	11
44	Breakthrough Medical Devices and the 21st Century Cures Act. Annals of Internal Medicine, 2016, 164, 500.	3.9	11
45	Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. Clinical Pharmacology and Therapeutics, 2017, 102, 290-296.	4.7	11
46	Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling Up Access to Treatment. PLoS Medicine, 2014, 11, e1001738.	8.4	9
47	Surgical Applications of 3-Dimensional Printing and Precision Medicine. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 305.	2.2	9
48	Precision medicine and the FDA's draft guidance on laboratory-developed tests. Nature Biotechnology, 2015, 33, 449-451.	17.5	9
49	Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies. Health Affairs, 2016, 35, 219-226.	5.2	9
50	Major Events in the Life Course of New Drugs, 2000â€“2016. New England Journal of Medicine, 2019, 380, e12.	27.0	9
51	European Medicines Agencyâ€™s Priority Medicines Scheme at 2ÂYears: An Evaluation of Clinical Studies Supporting Eligible Drugs. Clinical Pharmacology and Therapeutics, 2020, 107, 541-552.	4.7	9
52	Paying for Prescription Drugs in the New Administration. JAMA - Journal of the American Medical Association, 2021, 325, 819.	7.4	9
53	Life Cycle of Medical Product Rules Issued by the US Food and Drug Administration. Journal of Health Politics, Policy and Law, 2014, 39, 751-780.	1.9	8
54	Accelerating innovation in rapid diagnostics and targeted antibacterials. Nature Biotechnology, 2015, 33, 589-590.	17.5	8

#	Article	IF	Citations
55	Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019. JAMA Network Open, 2022, 5, e226479.	5.9	8
56	Public referendum on drug prices in the US: will it bring relief?. BMJ, The, 2016, 355, i5657.	6.0	7
57	Challenges in the Development of Novel Cardiovascular Therapies. Clinical Pharmacology and Therapeutics, 2017, 102, 194-196.	4.7	6
58	Improving the Study of New Medicines for Children With Rare Diseases. JAMA Pediatrics, 2018, 172, 7.	6.2	6
59	Prescription Opioid Epidemic and Trends in the Clinical Development of New Pain Medications. Mayo Clinic Proceedings, 2019, 94, 2437-2443.	3.0	5
60	Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D. JAMA Oncology, 2022, 8, 155.	7.1	5
61	Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010â€“2018. Journal of General Internal Medicine, 2022, , .	2.6	5
62	Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections. American Journal of Law and Medicine, 2016, 42, 429-450.	0.2	4
63	New EU regulation on health technology assessment of cancer medicines. Lancet Oncology, The, 2022, 23, e58.	10.7	4
64	New Regulatory Paradigms for Innovative Drugs to Treat Pediatric Diseases. JAMA Pediatrics, 2014, 168, 879.	6.2	3
65	Evaluating New Rules on Transparency in Cancer Research and Drug Development. JAMA Oncology, 2019, 5, 461.	7.1	3
66	New Treatments for Migraineâ€”Therapeutic Ratings and Comparative Coverage in the US, Canada, and Europe. JAMA Internal Medicine, 2022, 182, 101.	5.1	3
67	Coverage of New Drugs in Medicare Part D. Milbank Quarterly, 2022, 100, 562-588.	4.4	3
68	Retinal Implants and Medicare Reimbursement Policies for Breakthrough Treatments in Ophthalmology. JAMA Ophthalmology, 2015, 133, 373.	2.5	2
69	Availability of paediatric information in European Medicines Agency approvals. The Lancet Child and Adolescent Health, 2018, 2, e9.	5.6	2
70	Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.. Journal of Clinical Oncology, 2018, 36, 6573-6573.	1.6	2
71	Measuring the Value of New Medications and Implications for Medicareâ€™s Proposed Part B Drug Payment Model. JAMA Oncology, 2016, 2, 1125.	7.1	1
72	Profiting from Most-Favored Customer Procurement Rules: Evidence from Medicaid. Proceedings - Academy of Management, 2021, 2021, 10106.	0.1	1

#	Article	IF	Citations
73	Clinical benefit and prices of cancer drugs in the United States and Europe.. Journal of Clinical Oncology, 2019, 37, 6638-6638.	1.6	1
74	Public Participation in Drafting of the 21st Century Cures Act. Journal of Law, Medicine and Ethics, 2017, 45, 212-220.	0.9	0
75	Expansion of the Priority Review Voucher Program Under the 21st Century Cures Act: Implications for Innovation and Public Health. American Journal of Law and Medicine, 2018, 44, 329-341.	0.2	0
76	Increasing the Transparency of FDA Review to Enhance the Innovation Process. , 2019, , 185-195.		0
77	Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.. Journal of Clinical Oncology, 2020, 38, 7052-7052.	1.6	0
78	Launch prices and price developments of cancer drugs in the United States and Europe.. Journal of Clinical Oncology, 2020, 38, 2006-2006.	1.6	0
79	Pivotal trial endpoints and prices of cancer drugs in the US and Europe.. Journal of Clinical Oncology, 2020, 38, 2077-2077.	1.6	0
80	Trends in Launch Prices and Price Increases for New Medicines for Urological Cancers. Journal of Urology, 0, , .	0.4	0